# To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

Source: https://onco.cc/trials/nct05541822/  
OnCo record `nct05541822` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Lazertinib in advanced solid tumours, run by Abion Inc, now recruiting.

## Summary

To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation is a phase 2 interventional study registered as NCT05541822 by Abion Inc, with 178 participants planned, started 2023-01-17 and due to reach its primary completion in 2029-02. Interventions recorded: Vabametkib and Lazertinib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05541822
- Phase: 2
- Setting: A Phase 2 Multicenter, Open-Label, Parallel Cohort Expansion Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-Mesenchymal-epithelial Transition Factor (c-MET) Dysregulation
- Sponsor: Abion Inc
- Enrolled: 178

## Sources

- ClinicalTrials.gov NCT05541822: https://clinicaltrials.gov/study/NCT05541822

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Lazertinib](https://onco.cc/drugs/lazertinib/)

---
JSON: https://onco.cc/api/v1/entities/nct05541822.json